BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 15800715)

  • 1. Prevention of febrile neutropenia in cancer patients by probiotic strain Enterococcus faecium M-74. Pilot study phase I.
    Mego M; Ebringer L; Drgona L; Mardiak J; Trupl J; Greksak R; Nemova I; Oravcova E; Zajac V; Koza I
    Neoplasma; 2005; 52(2):159-64. PubMed ID: 15800715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of febrile neutropenia in cancer patients by probiotic strain Enterococcus faecium M-74. Phase II study.
    Mego M; Koncekova R; Mikuskova E; Drgona L; Ebringer L; Demitrovicova L; Nemova I; Trupl J; Mardiak J; Koza I; Zajac V
    Support Care Cancer; 2006 Mar; 14(3):285-90. PubMed ID: 16175356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
    Timmer-Bonte JN; de Boo TM; Smit HJ; Biesma B; Wilschut FA; Cheragwandi SA; Termeer A; Hensing CA; Akkermans J; Adang EM; Bootsma GP; Tjan-Heijnen VC
    J Clin Oncol; 2005 Nov; 23(31):7974-84. PubMed ID: 16258098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of neutropenia on delivering planned chemotherapy for solid tumours.
    Khan S; Dhadda A; Fyfe D; Sundar S
    Eur J Cancer Care (Engl); 2008 Jan; 17(1):19-25. PubMed ID: 18181887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Fever profile of febrile neutropenia in patients treated with cancer chemotherapy for hematological malignancies].
    Tamai Y; Imataki O; Kawakami K
    Gan To Kagaku Ryoho; 2010 May; 37(5):859-62. PubMed ID: 20495316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain.
    Mayordomo JI; López A; Viñolas N; Castellanos J; Pernas S; Domingo Alonso J; Frau A; Layola M; Antonio Gasquet J; Sánchez J;
    Curr Med Res Opin; 2009 Oct; 25(10):2533-42. PubMed ID: 19722781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy.
    Timmer-Bonte JN; Adang EM; Termeer E; Severens JL; Tjan-Heijnen VC
    J Clin Oncol; 2008 Jan; 26(2):290-6. PubMed ID: 18182670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use and effectiveness of granulocyte colony-stimulating factor in primary prophylaxis for febrile neutropenia in the outpatient setting.
    Tuffaha HW; Treish IM; Zaru L
    J Oncol Pharm Pract; 2008 Sep; 14(3):131-8. PubMed ID: 18524866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study.
    Weycker D; Malin J; Kim J; Barron R; Edelsberg J; Kartashov A; Oster G
    Clin Ther; 2009 May; 31(5):1069-81. PubMed ID: 19539108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin.
    Chamilos G; Bamias A; Efstathiou E; Zorzou PM; Kastritis E; Kostis E; Papadimitriou C; Dimopoulos MA
    Cancer; 2005 Jun; 103(12):2629-35. PubMed ID: 15856427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prevention of febrile neutropenia.
    Pascoe J; Cullen M
    Curr Opin Oncol; 2006 Jul; 18(4):325-9. PubMed ID: 16721125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy.
    Shayne M; Culakova E; Poniewierski MS; Wolff D; Dale DC; Crawford J; Lyman GH
    Cancer; 2007 Oct; 110(7):1611-20. PubMed ID: 17705197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.
    Lee SJ; Cho SH; Yoon JY; Hwang JE; Bae WK; Shim HJ; Chung IJ
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):159-66. PubMed ID: 19479256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immediate vs. delayed imipenem treatment in cancer patients with profound neutropenia induced by high-dose chemotherapy: results of a randomized study.
    García-Sáenz JA; Martín M; Casado A; Pérez-Segura P; Manrique I; Flores L; Macias JA; Cámara JC; Perezagua C; Díaz-Rubio E
    Rev Esp Quimioter; 2002 Sep; 15(3):257-63. PubMed ID: 12582429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chemotherapy-induced febrile neutropenia: about 200 episodes. Clinical, microbiological and therapeutic characteristics].
    Gharbi O; Ben Hadj Hassen S; Kaabia N; Limam S; Hadj Amor M; Ben Fatma L; Landolsi A; Hochlef M; Letaief A; Boukadida J; Ben Ahmed S
    Pathol Biol (Paris); 2008 May; 56(3):154-7. PubMed ID: 18178025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation.
    Castagnola E; Fontana V; Caviglia I; Caruso S; Faraci M; Fioredda F; Garrè ML; Moroni C; Conte M; Losurdo G; Scuderi F; Bandettini R; Tomà P; Viscoli C; Haupt R
    Clin Infect Dis; 2007 Nov; 45(10):1296-304. PubMed ID: 17968824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of granulocyte colony stimulating factor (G-CSF) in chemotherapy induced neutropenia.
    Ghalaut PS; Sen R; Dixit G
    J Assoc Physicians India; 2008 Dec; 56():942-4. PubMed ID: 19322972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of febrile neutropenia and neutropenic infections in elderly patients receiving anthracycline-based chemotherapy for breast cancer without primary prophylaxis with colony-stimulating factors.
    Minisini A; Spazzapan S; Crivellari D; Aapro M; Biganzoli L
    Crit Rev Oncol Hematol; 2005 Feb; 53(2):125-31. PubMed ID: 15661563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients.
    Oude Nijhuis C; Kamps WA; Daenen SM; Gietema JA; van der Graaf WT; Groen HJ; Vellenga E; Ten Vergert EM; Vermeulen KM; de Vries-Hospers HG; de Bont ES
    J Clin Oncol; 2005 Oct; 23(30):7437-44. PubMed ID: 16234511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low mannose-binding lectin concentration is associated with severe infection in patients with hematological cancer who are undergoing chemotherapy.
    Vekemans M; Robinson J; Georgala A; Heymans C; Muanza F; Paesmans M; Klastersky J; Barette M; Meuleman N; Huet F; Calandra T; Costantini S; Ferrant A; Mathissen F; Axelsen M; Marchetti O; Aoun M
    Clin Infect Dis; 2007 Jun; 44(12):1593-601. PubMed ID: 17516403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.